Song, Haiqing
Wang, Yuan
Ma, Qingfeng
Chen, Huisheng
Liu, Bo
Yang, Yi
Zhu, Jianguo
Zhao, Shigang
Jin, Xiaoping
Li, Yongqiu
Wang, Yanyong
Zhu, Runxiu
Zhao, Liandong
Liu, Junyan
Feng, Wuwei
Liu, Rui
Ji, Xunming
Wang, Yuping
Clinical trials referenced in this document:
Documents that mention this clinical trial
Thrombolysis with Recombinant Human Prourokinase 4.5–6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial
https://doi.org/10.1007/s40263-023-01051-2
Funding for this research was provided by:
Tasly Biopharmaceuticals Co., Ltd.
Article History
Accepted: 2 November 2023
First Online: 29 November 2023
Declarations
:
: This study was sponsored by Tasly Biopharmaceutical Co., Ltd. And Tasly bio-pharmaceutical Co., Ltd, funded the open access fee.
: Rui Liu reports being an employee of Tasly Biopharmaceuticals Co., Ltd. Haiqing Song, Yuan Wang, Qingfeng Ma, Huisheng Chen, Bo Liu, Yi Yang, Jianguo Zhu, Shigang Zhao, Xiaoping Jin, Yongqiu Li, Yanyong Wang, Runxiu Zhu, Liandong Zhao, Junyan Liu, Wuwei Feng, Xunming Ji, and Yuping Wang declare no other potential conflict of interest that might be relevant to this article.
: The study was approved by the Xuanwu Hospital Ethics Committee, Capital Medical University (Approval number [2018]010).
: All study participants or their legally authorized representative provided informed consent.
: Not applicable.
: Data are available to researchers on request for the purpose of reproducing the results or replicating the procedure by directly contacting the corresponding author.
: Not applicable.
: Drs. Song HQ and Wang Y contributed equally as co-first authors. Drs. Wang YP and Ji XM had full access to all the data in the study and were responsible for the integrity of the data and the accuracy of the data analysis. Drs. Song HQ, Ma QF, Ji XM, and Wang YP contributed to the study concept and design. All authors acquired, analyzed, and interpreted the data. Dr. Wang Y wrote the first draft the manuscript. Drs. Feng W, Ji XM, and Wang YP provided critical revision of the manuscript for important intellectual content. All authors provided administrative, technical, or material support, and approved the final manuscript.